

Vedolizumab (Entyvio®)

Selected References:

- Barrau M, et al. 2023. What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?. *J Clin Med.* 12(23):7495.
- Bell C, et al. 2021. Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. *J Gastroenterol Hepatol*;36(10):2640-2648. PMID: 34110640 DOI: 10.1111/jgh.15574
- Caballero-Mateos AM, et al. 2023. IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond. *J Clin Med.* 12(19):6192.
- Chugh R. 2023. Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results from the PIANO registry. *Am J Gastroenterol.* DOI: 10.14309/ajg.0000000000002553.
- Ding N, et al. 2022. Management of biologics in pregnant, lactating patients with inflammatory bowel disease and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements. *J Clin Pharm Ther.* 47(12):1952-1965.
- Gisbert JP, et al. 2023. Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?. *J Crohns Colitis.* 17 (6):995-1009.
- Gisbert JP, et al. 2020. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. *Drugs*;80(11):1085-1100. PMID: 32562207 DOI: 10.1007/s40265-020-01346-4
- Honap S, et al. 2023. An update on the safety of long-term vedolizumab use in inflammatory bowel disease. *Expert Opin Drug Saf.* 22 (9):767-776.
- Julsgaard M, et al. 2017. Vedolizumab safety in pregnancy and newborn outcomes. *Gut*; 66(10):1866-1867.
- Julsgaard M, et al. 2018. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. *Gastroenterology* 154: 752-765.
- Lahat A, et al. 2018. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. *J Crohns Colitis*; 12:120-3.
- Lamb CA, et al. 2019. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* ;68(Suppl 3):s1-s106. PMID: 31562236 PMCID: PMC6872448 DOI: 10.1136/gutjnl-2019-318484
- Laube R, et al. 2021. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. *Expert Opin Drug Saf* ;20(3):275-292. PMID: 33412078 DOI: 10.1080/14740338.2021.1873948
- Mahadevan U, et al. 2017. Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease. *Aliment Pharmacol Ther*; 45:941-950.
- Mahadevan U, et al. 2017. Editorial: vedolizumab in pregnancy – is gut selectivity as good for baby as it is for mum? Authors' reply. *Aliment Pharmacol Ther.* 45(9):1284.
- Meyer A, et al. 2024. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol.* DOI: 10.1016/j.cgh.2023.12.029.
- Mitrova K, et al. 2022. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. *Journal of Crohn's & colitis.* Vol 16, 12: 1808-1815.
- Moens A, et al. 2019. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. *J Crohns Colitis* 13(1): 12-13.
- Moens A, et al. 2020. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. *Aliment Pharmacol Ther* 51(1): 129-138.
- Nielsen OH. 2022. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol.* 20(1):74-87.

- Pugliese D, et al. 2024. New drugs for the treatment of IBD during conception, pregnancy, and lactation. *Dig Liver Dis.* 56 (2): 235-241.
- Rosario M, et al. 2017. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. *Clin Pharmacokinet.* 2017; 56(11): 1287-1301. PMID: 28523450
- Sheridan J, et al. 2017. Letter: Vedolizumab in Pregnancy. *J Crohns Colitis;* 11(8):1025-1026.
- Shitrit AB-G A, et al. 2019. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: A first perspective comparison study. *Am J Gastroenterol* 114(7): 1172-1175.
- Sun W, et al. 2021. Vedolizumab concentrations in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease. *Clin Pharmacokinet.* 60:811-8.
- Takeda Pharmaceuticals America, Inc. 2018. Entyvio product label. Available at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c>

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Vedolizumab (Entyvio®)

Selected References:

- Andrade C. 2020. Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron. *J Clin Psychiatry;*81(3):20f13472
- Anderka M, et al. 2012. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol;* 94(1):22-30.
- Briggs GG, Freeman RK. 2014. *Drugs in Pregnancy and Lactation.* 10th edition. Philadelphia, PA: Wolters Kluwer (online version).
- Kaplan YC, et al. 2019. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systemic review and meta-analysis. *Reprod Toxicol;* 86 Jun:1-13.
- Cao X, et al. 2022. Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis. *Front Pharmacol,* 13(951072).

- Cohen R, et al. 2014. Intestinal obstruction in pregnancy by ondansetron. *Reprod Toxicol*. 2014 Oct 24;50C:152-153.
- Colvin L, et al. 2013. Off-label use of ondansetron in pregnancy in Western Australia. *Biomed Res Int*. 2013:909860.
- Danielsson B, Wikner BN, Kallen B. 2014. Use of ondansetron during pregnancy and congenital malformations in the infant. *Reprod Toxicol* 50:134-7.
- Diav-Citrin O, et al. 2017. Pregnancy outcome following in utero exposure to ondansetron: A prospective comparative, observational cohort study. *Reprod Toxicol*; 72:203.
- Dormuth CR, et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. 2021. Comparison of Pregnancy Outcomes of Patients Treated with Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. *JAMA Netw Open*; 4(4):e215329.
- Einarson AK, et al. 2004. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. *BJOG*;111:940-3.
- Elkomy MH, et al. 2015. Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. *Clin Pharmacol Ther*. 97:167-76.
- Fejzo MS, et al. 2016. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. *Reprod Toxicol* 62: 87-91.
- Food and Drug Administration. 2012. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran>. Accessed 2018 & 2022.
- Jelting Y, et al. 2017. Preventing nausea and vomiting in women undergoing regional anesthesia for cesarean section: Challenges and solutions. *Local Reg Anesth*, 10:83-90.
- Larrimer MB, et al. 2014. Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. *Am J Obstet Gynecol* 210 (3): 270. e1-7
- Lavecchia M, et al. 2018. Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review. *J Obstet Gynaecol Can*. 40(7):910-918.
- Lemon LS, et al. 2020. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. *Int J Epidemiol*;49(2):648-656.
- Masarwe S, et al. 2023. Ondansetron use during pregnancy: Birth defects and obstetric outcomes. *Clin Nurs Res*, 32(4):705-711.
- Pasternak B. 2013. Ondansetron in pregnancy and risk of adverse fetal outcomes. *N Engl J Med* 368:814-823.
- Picot C, et al. 2020. Risk of malformation after ondansetron in pregnancy: An updated systemic review and meta-analysis. *Birth Defects Res*;112(13):996-1013.
- Reis ACC, et al. 2023. Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats. *Regul Toxicol Pharmacol*, 137:105302.
- Sakran R, et al. 2021. Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. *Reprod Toxicol*; 99:9-14.
- Schragger NL, et al. 2023. The association of nausea and vomiting of pregnancy, its treatments, and select birth defects: Findings from the National Birth Defect Prevention Study. *Birth Defects Res*, 115(3):275-289.
- Suarez EA, et al. 2021. Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. *Pharmacoepidemiol Drug Saf*; 30(2):114-125.
- Suarez EA, et al. 2021. Ondansetron use in early pregnancy and the risk of miscarriage. *Pharmacoepidemiol Drug Saf*; 30(2):103-113.
- Zhao W, et al. 2020. Retrospective comparison of the safety and effectiveness of dexmedetomidine versus standard of care before and during cesarean delivery in a maternity unit in Zhengzhou, China. *Med Sci Monit*, 26:e925709.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Vedolizumab (Entyvio®)

Selected References:

- Andersen, J. B, et al. 2023. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. *European journal of neurology*, 30(1), 162-171.
- Ciplea, A. I, et al. 2020. Exposure to natalizumab during pregnancy and lactation is safe – Commentary. *Multiple sclerosis (Houndmills, Basingstoke, England)*, 26(8), 892-893.
- D’Amico, E, et al. 2021. Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. *Multiple sclerosis (Houndmills, Basingstoke, England)*, 27(14), 2284-2287.
- Ebrahimi N, et al. 2014. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. *Mult Scler.* 2015 Feb;21(2):198-205.
- Friend S, et al. 2016. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. *BMC Neurol.* Aug 24;16(1):150
- Gklinos, P, et al. 2023. Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide. *Pharmaceuticals (Basel, Switzerland)*,16(5), 770.
- Haghikia A, , et al. 2014. Natalizumab use during the third trimester of pregnancy. *JAMA Neurol* 71(7): 891-895.
- Mahadevan U, , et al. 2019. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. *Gastroenterology.* Apr;156(5):1508-1524.
- Massarotti, C., et al. 2021. Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. *Journal of clinical medicine*, 10(22), 5401
- O’Leary, S, et al. 2023. Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis. *Journal of infusion nursing : the official publication of the Infusion Nurses Society*, 46(6), 347-359.
- Oreja-Guevara, C, et al. 2023. Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements. *Cureus*, 15(8), e44056
- Peng A, et al. 2018. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. *J Neurol Sci.* 2019 Jan 15;396:202-205.

- Portaccio E, et al. 2018. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. I: Fetal risks. *Neurology*. Page #s or journal volume?
- Simone, I. L, et al. 2021. Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies. *Frontiers in neurology*,12, 697974.
- Tysabri. Drug Approval Package. Pharmacology reviews. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_natalizumab.cfm
- Ramesh, V, et al. 2022. Adverse Obstetric Outcomes in Pregnant Women Using Natalizumab for the Treatment of Multiple Sclerosis: A Systematic Review. *Cureus*,14(10), e29952

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Vedolizumab (Entyvio®)

Selected References:

- Benyamini L, et al. 2005. The safety of amoxicillin/clavulanic acid and cefuroxime during lactation. *Ther Drug Monit.* 27:499-502.
- Chu YN, et al. 2019. Toxic epidermal necrolysis in an infant induced by drug intake through breast milk. *Dermatologica Sinica.* 37:86-89.
- Czeizel AE, et al. 2001. Use of cephalosporins during pregnancy and in the presence of congenital anomalies: a population-based, case-control study. *Am J Obstet Gynecol* 184:1289-1896.
- Ilett KF, et al. 2006. Transfer of probenecid and cephalixin into breast milk. *Ann Pharmacother.* 40:986-989.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol.* 168:1393-1399.
- Kafetzi D, et al. 1981. Passage of cephalosporins and amoxicillin into the breast milk. *Acta Paediatr Scand* 70:285-288.
- Teva Pharmaceuticals. 2020. Cephalixin product label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19307ff0-71de-477b-965d-ea243e5ede3a>.

[Accessed March 27 2024]

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.

Vedolizumab (Entyvio®)

Selected References:

- Anghelache M, et al. 2022. Multiple sclerosis in pregnancy- current neurological considerations. Romanian Journal of Pediatrics, 71(2):55-59.
- Novartis Pharmaceuticals Corporation. 2022. Mayzent Drug Label, Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3>
- Ruggieri S, et al. 2022. Ponesimod in the treatment of relapsing forms of multiple sclerosis: a update on the emerging clinical data. Degenerative Neurological and Neuromuscular Disease, 12:61-73.
- Sabsabi S, et al. 2023. Clinical evaluation of siponimod for the treatment of secondary progressive multiple sclerosis: pathophysiology, efficacy, safety, patient acceptability, and adherence. Patient Preference and Adherence, 16:1307-1319.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2024.